EXT2 promotes sarcoma progression and immune evasion via the AKT/c-Myc/PD-L1 axis: a multi-omics and validation study.

J Transl Med · 2026 · PMC13123158 · PMID 41857664

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Several other strata did not reach statistical significance (see Supplementary Table 4 and Supplementary Fig. 1 ), underscoring that the adverse prognostic impact of EXT2 is robust in key subgroups while varying by clinical context.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.